|
1
|
Blazar BR, Murphy WJ and Abedi M: Advances
in graft-versus-host disease biology and therapy. Nat Rev Immunol.
12:443–458. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kamiryo Y, Eto M, Yamada H, et al: Donor
CD4 T cells are critical in allogeneic stem cell transplantation
against murine solid tumor. Cancer Res. 69:5151–5158. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang H, Asavaroengchai W, Yeap BY, et al:
Paradoxical effects of IFN-gamma in graft-versus-host disease
reflect promotion of lymphohematopoietic graft-versus-host
reactions and inhibition of epithelial tissue injury. Blood.
113:3612–3619. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang Y, Wang H, Yu H, et al: IFN-γ
promotes graft-versus-leukemia effects without directly interacting
with leukemia cells in mice after allogeneic hematopoietic cell
transplantation. Blood. 118:3721–3724. 2011.
|
|
5
|
Taylor PA, Lees CJ and Blazar BR: The
infusion of ex vivo activated and expanded CD4(+)CD25(+) immune
regulatory cells inhibits graft-versus-host disease lethality.
Blood. 99:3493–3499. 2002.
|
|
6
|
Ikeda H, Old LJ and Schreiber RD: The
roles of IFN gamma in protection against tumor development and
cancer immunoediting. Cytokine Growth Factor Rev. 13:95–109. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pratheeshkumar P and Kuttan G: Modulation
of cytotoxic T lymphocyte, natural killer cell, antibody-dependent
cellular cytotoxicity, and antibody-dependent complement-mediated
cytotoxicity by Vernonia cinerea L. and vernolide-A in
BALB/c mice via enhanced production of cytokines IL-2 and IFN-γ.
Immunopharmacol Immunotoxicol. 34:46–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moreno M, Molling JW, von
Mensdorff-Pouilly S, et al: IFN-gamma-producing human invariant NKT
cells promote tumor-associated antigen-specific cytotoxic T cell
responses. J Immunol. 181:2446–2454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng G, Mao D, Che Y, et al: The
phenotypic fate of bone marrow-derived stem cells in acute kidney
injury. Cell Physiol Biochem. 32:1517–1527. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jia X, Xie X, Feng G, et al: Bone
marrow-derived cells can acquire renal stem cells properties and
ameliorate ischemia-reperfusion induced acute renal injury. BMC
Nephrol. 13:1052012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou M, Wang L, Su W, et al: Assessment of
therapeutic efficacy of liposomal nanoparticles mediated gene
delivery by molecular imaging for cancer therapy. J Biomed
Nanotechnol. 8:742–750. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Su W, Wang L, Zhou M, et al: Human
embryonic stem cell-derived endothelial cells as cellular delivery
vehicles for treatment of metastatic breast cancer. Cell
Transplant. 22:2079–2090. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang YG, Qi J, Wang MG and Sykes M:
Donor-derived interferon gamma separates graft-versus-leukemia
effects and graft-versus-host disease induced by donor CD8 T cells.
Blood. 99:4207–4215. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bishop MR: Nonmyeloablative allogeneic
hematopoietic stem cell transplantation for metastatic breast
cancer. Clin Breast Cancer. 4:39–45. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Asavaroengchai W, Wang H, Wang S, et al:
An essential role for IFN-gamma in regulation of alloreactive CD8 T
cells following allogeneic hematopoietic cell transplantation. Biol
Blood Marrow Transplant. 13:46–55. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seki N, Brooks AD, Carter CR, et al:
Tumor-specific CTL kill murine renal cancer cells using both
perforin and Fas ligand-mediated lysis in vitro, but cause tumor
regression in vivo in the absence of perforin. J Immunol.
168:3484–3492. 2002. View Article : Google Scholar
|
|
17
|
Connett JM, Hunt SR, Hickerson SM, Wu SJ
and Doherty GM: Localization of IFN-gamma-activated Stat1 and IFN
regulatory factors 1 and 2 in breast cancer cells. J Interferon
Cytokine Res. 23:621–630. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yim JH, Ro SH, Lowney JK, Wu SJ, Connett J
and Doherty GM: The role of interferon regulatory factor-1 and
interferon regulatory factor-2 in IFN-gamma growth inhibition of
human breast carcinoma cell lines. J Interferon Cytokine Res.
23:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gage I, Schnitt SJ, Recht A, et al: Skin
recurrences after breast-conserving therapy for early-stage breast
cancer. J Clin Oncol. 16:480–486. 1998.PubMed/NCBI
|
|
20
|
Chen C, Guo L, Shi M, et al: Modulation of
IFN-gamma receptor 1 expression by AP-2α influences IFN-γ
sensitivity of cancer cells. Am J Pathol. 180:661–671.
2012.PubMed/NCBI
|
|
21
|
Nishikawa H, Kato T, Tawara I, et al:
IFN-gamma controls the generation/activation of CD4+ CD25+
regulatory T cells in antitumor immune response. J Immunol.
175:4433–4440. 2005.PubMed/NCBI
|
|
22
|
Gillmore R, Xue SA, Holler A, et al:
Detection of Wilms’ tumor antigen - specific CTL in tumor-draining
lymph nodes of patients with early breast cancer. Clin Cancer Res.
12:34–42. 2006.
|
|
23
|
Chen L, Huang TG, Meseck M, Mandeli J,
Fallon J and Woo SL: Rejection of metastatic 4T1 breast cancer by
attenuation of Treg cells in combination with immune stimulation.
Mol Ther. 15:2194–2202. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Duncan TJ, Rolland P, Deen S, et al: Loss
of IFN gamma receptor is an independent prognostic factor in
ovarian cancer. Clin Cancer Res. 13:4139–4145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan Z and Zhang Q: Molecular mechanisms of
lymphocyte-mediated cytotoxicity. Cell Mol Immunol. 2:259–264.
2005.PubMed/NCBI
|
|
26
|
Los M, Wesselborg S and Schulze-Osthoff K:
The role of caspases in development, immunity, and apoptotic signal
transduction: lessons from knockout mice. Immunity. 10:629–639.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ramirez-Montagut T, Chow A, Kochman AA, et
al: IFN-gamma and Fas ligand are required for graft-versus-tumor
activity against renal cell carcinoma in the absence of lethal
graft-versus-host disease. J Immunol. 179:1669–1680. 2007.
View Article : Google Scholar : PubMed/NCBI
|
